Search results

1139 results

Sorted by Relevance . Sort by Date

  1. Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (TA258)

    Evidence-based recommendations on erlotinib (Tarceva) for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer

  2. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)

    Evidence-based recommendations on botulinum toxin type A (Botox) for the prevention of headaches in adults with chronic migraine

  3. Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)

    Evidence-based recommendations on fulvestrant (Faslodex) for treating locally advanced or metastatic breast cancer

  4. Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (TA245)

    Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism (VTE) after total hip or knee replacement in adults

  5. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in atrial fibrillation (AF)

  6. Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)

    Evidence-based recommendations on fingolimod (Gilenya) for treating highly active relapsing–remitting multiple sclerosis (MS)

  7. Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA620)

    Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal

  8. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621)

    Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive

  9. HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries) (TA92)

    Evidence-based recommendations on HealOzone (ozone-releasing device) for treating tooth decay (occlusal pit/fissure caries/root caries)

  10. Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)

    Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for the treatment of chronic hepatitis B

  11. Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)

    Evidence-based recommendations on imatinib for treating unresectable and/or metastatic gastrointestinal stromal tumours (GIST/soft tissue sarcoma)

  12. Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)

    Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women

  13. Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)

    Evidence-based recommendations on raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

  14. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (TA157)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for the prevention of venous thromboembolism after hip or knee replacement surgery

  15. Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)

    Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir, Symmetrel) and zanamivir (Relenza) to prevent influenza (flu)

  16. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin (TA159)

    Evidence-based recommendations on spinal cord stimulation (SCS) for chronic pain of neuropathic or ischaemic origin in adults

  17. Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)

    Evidence-based recommendations on rituximab (MabThera) for the first-line treatment of chronic lymphocytic leukaemia (CLL)

  18. Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)

    Evidence-based recommendations on evacizumab (Avastin), soradenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for renal cell carcinoma

  19. Febuxostat for the management of hyperuricaemia in people with gout (TA164)

    Evidence-based recommendations on febuxostat (Adenuric) for the management of hyperuricaemia in people with gout

  20. Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)

    Evidence-based recommendations on machine perfusion systems and cold static storage of kidneys from deceased donors

  21. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)

    Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for the treatment of age-related macular degeneration (AMD)

  22. Routine antenatal anti-D prophylaxis for women who are rhesus D negative (TA156)

    Evidence-based recommendations on routine antenatal anti-D prophylaxis for women who are rhesus D negative

  23. Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)

    Evidence-based recommendations on amantadine (Lysovir, Symmetrel), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza (flu)

  24. Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)

    Evidence-based recommendations on sunitinib (Sutent) for the first-line treatment of advanced and/or metastatic renal cell carcinoma

  25. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (TA170)

    Evidence-based recommendations on rivaroxaban (Xarelto) for the prevention of venous thromboembolism after total hip or knee replacement in adults

  26. Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)

    Evidence-based recommendations on lenalidomide (Revlimid) for myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality

  27. Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)

    Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in people with alcohol dependence

  28. Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA326)

    Evidence-based recommendations on imatinib (Glivec) for adjuvant treatment of gastrointestinal stromal tumours (cancers in the digestive track)

  29. Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treatment and secondary prevention of deep vein thrombosis (DVT) or pulmonary embolism

  30. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra, Remsima) adalimumab (Humira) and golimumab (Simponi) for ulcerative colitis after..

  31. Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)

    Evidence-based recommendations on axitinib (Inlyta) for treating advanced renal cell carcinoma (RCC) (kidney cancer) when prior systemic treatment has failed

  32. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)

    Evidence-based recommendations on apixaban (Eliquis) for treating and preventing deep vein thrombosis (DVT) or pulmonary embolism

  33. Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)

    Evidence-based recommendations on vedolizumab (Entyvio) for treating moderately to severely active ulcerative colitis in adults

  34. Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for treating untreated chronic lymphocytic leukaemia

  35. Omalizumab for previously treated chronic spontaneous urticaria (TA339)

    Evidence-based recommendations on omalizumab (Xolair) for treating previously treated severe chronic spontaneous urticaria (hives)

  36. Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing adverse outcomes after acute management of acute coronary syndrome (ACS)

  37. Empagliflozin in combination therapy for treating type 2 diabetes (TA336)

    Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes

  38. Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)

    Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of overt hepatic encephalopathy